Icon (ICLR) Q1 Earnings Announcement Scheduled
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Earnings Release Date: Icon is set to announce its Q1 earnings on June 23rd after market close, with consensus EPS estimate at $2.43, reflecting a 23.8% year-over-year decline, and revenue expected to be flat at $2 billion.
- Historical Performance Review: Over the past two years, Icon has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, indicating a degree of stability in its financial performance.
- Expectation Adjustments: In the last three months, EPS estimates have seen no upward revisions and 10 downward adjustments, while revenue estimates have experienced 4 upward and 3 downward revisions, reflecting market caution regarding the company's future performance.
- Market Reaction: Icon's stock dropped after missing Q4 earnings expectations but rebounded following the conclusion of an accounting probe, highlighting market concerns over corporate governance and financial transparency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICLR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICLR
Wall Street analysts forecast ICLR stock price to rise
13 Analyst Rating
6 Buy
7 Hold
0 Sell
Moderate Buy
Current: 146.000
Low
172.00
Averages
202.67
High
222.00
Current: 146.000
Low
172.00
Averages
202.67
High
222.00
About ICLR
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Earnings Release Date: Icon is set to announce its Q1 earnings on June 23rd after market close, with consensus EPS estimate at $2.43, reflecting a 23.8% year-over-year decline, and revenue expected to be flat at $2 billion.
- Historical Performance Review: Over the past two years, Icon has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, indicating a degree of stability in its financial performance.
- Expectation Adjustments: In the last three months, EPS estimates have seen no upward revisions and 10 downward adjustments, while revenue estimates have experienced 4 upward and 3 downward revisions, reflecting market caution regarding the company's future performance.
- Market Reaction: Icon's stock dropped after missing Q4 earnings expectations but rebounded following the conclusion of an accounting probe, highlighting market concerns over corporate governance and financial transparency.
See More
- Earnings Report: Icon's Q4 non-GAAP EPS of $2.52 missed expectations by $0.22, indicating pressure on profitability, while revenue of $2.11 billion, up 3.4% year-over-year, exceeded forecasts by $170 million, showcasing the company's stability in the market.
- Future Guidance: The company projects 2026 full-year revenue between $7.85 billion and $8.15 billion, with adjusted diluted EPS expected in the range of $10.00 to $11.00, reflecting management's confidence in future growth and potentially attracting more investor interest.
- Accounting Probe Conclusion: Following the conclusion of the accounting probe, Icon's stock rebounded, indicating a restoration of market confidence in the company's governance and financial transparency, which may help stabilize its stock price.
- Rating Upgrade: BMO upgraded Icon to Outperform based on a valuation reassessment, a move that could further drive stock price increases and attract more institutional investor attention.
See More
- Disappointing Earnings: ICON Public Limited reported non-GAAP diluted earnings per share of $2.52 for Q4 2025, falling short of the $3.23 consensus by approximately 35%, indicating a significant decline in profitability.
- Weak Revenue Growth: The company achieved Q4 revenue of $2.1 billion, a 3% year-over-year increase that exceeded the $2.0 billion forecast, yet overall performance failed to meet high market expectations, reflecting ongoing challenges.
- Uncertain Future Outlook: ICON projected adjusted EPS for 2026 between $10.00 and $11.00, missing the consensus of $11.22, highlighting difficulties in restoring profitability.
- Impact of Accounting Probe: The company is restating its financials to reflect overstatements of revenue by 0.8% and 1.1% for 2023 and 2024, respectively, which may undermine investor confidence in its financial health.
See More
- Quarterly Revenue Growth: In Q4 2025, revenue reached $2.1125 billion, reflecting a 2.5% year-over-year increase, indicating the company's stable growth in the market despite economic challenges.
- Adjusted EBITDA Performance: The adjusted EBITDA for Q4 was $327.1 million, representing 15.5% of revenue, showcasing the company's ongoing efforts in cost control and operational efficiency, even as overall profit margins declined.
- Net Business Wins: The net business wins for Q4 amounted to $2.868 billion with a book-to-bill ratio of 1.36, indicating strong performance in new business acquisition, which enhances the sustainability of future revenues.
- Financial Guidance Outlook: The company projects 2026 revenue in the range of $7.85 billion to $8.15 billion, with adjusted diluted earnings per share expected between $10.00 and $11.00, reflecting management's confidence in future growth.
See More
- Financial Results Schedule: ICON plc plans to release its Q4 and full-year 2025 financial results after market close on May 27, 2026, followed by a conference call on May 28, 2026, at 8:00 AM ET, demonstrating the company's commitment to transparency.
- Compliance Notification: ICON plc received a written notice from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to the pending filing of its 20-F form for the year ended December 31, 2025, although this notice has no immediate impact on the listing or trading of its securities, indicating the company remains within compliance parameters.
- Compliance Plan Timeline: Nasdaq has provided ICON plc with 60 days to submit a plan to regain compliance, and the company anticipates filing the 20-F form before the conference call, which could quickly restore compliance and maintain investor confidence.
- Forward-Looking Statements: The statements from ICON plc include forward-looking information regarding the finalization of the 20-F form and the ability to regain compliance, highlighting the risks and uncertainties faced in management and operations, and cautioning investors about potential market volatility.
See More









